索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]沈泓婕,杨宇龙.结直肠息肉化学预防药物的研究进展[J].国际消化病杂志,2024,06:357-360.
点击复制

结直肠息肉化学预防药物的研究进展(PDF)

《国际消化病杂志》[ISSN:1673-534X/CN:31-1953/R]

期数:
2024年06期
页码:
357-360
栏目:
综述
出版日期:
2024-12-20

文章信息/Info

Title:
-
作者:
沈泓婕; 杨宇龙
330000 南昌大学第四临床医学院（沈泓婕）；330000 南昌大学附属康复医院消化内科（杨宇龙）
Author(s):
-
关键词:
结直肠息肉; 化学预防; 药物治疗
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-534X.2024.06.002
文献标识码:
-
摘要:
结直肠息肉可以进展为结直肠癌（CRC），因此预防结直肠息肉的发生、进展可以减轻CRC的疾病负担。目前结直肠息肉的预防和治疗以结肠镜检查及结肠镜下切除为主，结直肠息肉切除后存在复发的风险。阿司匹林、舒林酸、塞来昔布、罗非昔布、二甲双胍和小檗碱等药物具有化学预防结直肠息肉的潜力。该文就结直肠息肉化学预防药物的研究进展作一综述。
Abstract:
-

参考文献/References

1Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791.3Lambert R, Kudo SE, Vieth M, et al. Pragmatic classification of superficial neoplastic colorectal lesions[J]. Gastrointest Endosc, 2009, 70(6): 1182-1199.
4Shussman N, Wexner SD. Colorectal polyps and polyposis syndromes[J]. Gastroenterol Rep (Oxf), 2014, 2(1): 1-15.
5 覃弦, 宋军, 侯晓华. 结直肠息肉内镜下诊断及治疗进展[J]. 中华消化内镜杂志, 2021, 38(12): 1040-1046.
6Heer E, Ruan Y, Mah B, et al. The efficacy of chemopreventive agents on the incidence of colorectal adenomas: A systematic review and network meta-analysis[J]. Prev Med, 2022, 162: 107169.
7Hybiak J, Broniarek I, Kiryczyński G, et al. Aspirin and its pleiotropic application[J]. Eur J Pharmacol, 2020, 866: 172762.
8 方瑄, 陈洪生, 李国东, 等. 异常隐窝灶治疗的研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 376-379.
9Mereto E, Frencia L, Ghia M. Effect of aspirin on incidence and growth of aberrant crypt foci induced in the rat colon by 1,2-dimethylhydrazine[J]. Cancer Lett, 1994, 76(1): 5-9.
10 Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer[J]. N Engl J Med, 2003, 348(10): 883-890.
11 Benamouzig R, Uzzan B, Deyra J, et al. Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial[J]. Gut, 2012, 61(2): 255-261.
12 Hull MA, Sprange K, Hepburn T, et al. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial[J]. Lancet, 2018, 392(10164): 2583-2594.
13 Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention[J]. Nat Rev Cancer, 2016, 16(3): 173-186.
14 Zhao R, Coker OO, Wu J, et al. Aspirin reduces colorectal tumor development in mice and gut microbes reduce its bioavailability and chemopreventive effects[J]. Gastroenterology, 2020, 159(3): 969-983. e4.
15 Zhang Y, Chan AT, Meyerhardt JA, et al. Timing of aspirin use in colorectal cancer chemoprevention: a prospective cohort study[J]. J Natl Cancer Inst, 2021, 113(7): 841-851.
16 Downing A, Fenton H, Nickerson C, et al. Colorectal polyp outcomes after participation in the seAFOod polyp prevention trial: Evidence of rebound elevated colorectal polyp risk after short-term aspirin use[J]. Aliment Pharmacol Ther, 2023, 58(6): 562-572.
17 Takayama T, Nagashima H, Maeda M, et al. Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps[J]. Clin Cancer Res, 2011, 17(11): 3803-3811.
18 Neuhann TM, Haub K, Steinke-Lange V, et al. Long-term chemoprevention in patients with adenomatous polyposis coli: an observational study[J]. Fam Cancer, 2022, 21(4): 463-472.
19 Balaguer F, Stoffel EM, Burke CA, et al. Combination of sulindac and eflornithine delays the need for lower gastrointestinal surgery in patients with familial adenomatous polyposis: post hoc analysis of a randomized clinical trial[J]. Dis Colon Rectum, 2022, 65(4): 536-545.
20 Davis JS, Kanikarla-Marie P, Gagea M, et al. Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development[J]. BMC Cancer, 2020, 20(1): 871.
21 Zhang Z, Ghosh A, Connolly PJ, et al. Gut-restricted selective cyclooxygenase-2 (COX-2) inhibitors for chemoprevention of colorectal cancer[J]. J Med Chem, 2021, 64(15): 11570-11596.
22 Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas[J]. N Engl J Med, 2006, 355(9): 873-884.
23 Thompson PA, Ashbeck EL, Roe DJ, et al. Celecoxib for the prevention of colorectal adenomas: results of a suspended randomized controlled trial[J]. J Natl Cancer Inst, 2016, 108(12): djw151.
24 Veettil SK, Teerawattanapong N, Ching SM, et al. Effects of chemopreventive agents on the incidence of recurrent colorectal adenomas: a systematic review with network meta-analysis of randomized controlled trials[J]. Onco Targets Ther, 2017, 10: 2689-2700.
25 孙根林, 王建荣, 游善喜. 塞来昔布治疗结直肠息肉的研究[J].实用临床医药杂志, 2016, 20(19): 141-142.
26 Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas[J]. Gastroenterology, 2006, 131(6): 1674-1682.
27 Triggle CR, Mohammed I, Bshesh K, et al. Metformin: Is it a drug for all reasons and diseases?[J]. Metabolism, 2022, 133: 155223.
28 Hosono K, Endo H, Takahashi H, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase[J]. Mol Carcinog, 2010, 49(7): 662-671.
29 Marks AR, Pietrofesa RA, Jensen CD, et al. Metformin use and risk of colorectal adenoma after polypectomy in patients with type 2 diabetes mellitus[J]. Cancer Epidemiol Biomarkers Prev, 2015, 24(11): 1692-1698.
30 Higurashi T, Hosono K, Takahashi H, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial[J]. Lancet Oncol, 2016, 17(4): 475-483.
31 Jaromy M, Miller JD. Pharmacologic mechanisms underlying antidiabetic drug metformin's chemopreventive effect against colorectal cancer[J]. Eur J Pharmacol, 2021, 897: 173956.
32 周军挺, 王丽, 吴婷, 等. 小檗碱抗人结直肠腺癌的作用及其机制[J]. 中草药, 2017, 48(3): 519-525.
33 Deng J, Zhao L, Yuan X, et al. Pre-administration of berberine exerts chemopreventive effects in AOM/DSS-Induced colitis-associated carcinogenesis mice via modulating inflammation and intestinal microbiota[J]. Nutrients, 2022, 14(4): 726.
34 Yan S, Chang J, Hao X, et al. Berberine regulates short-chain fatty acid metabolism and alleviates the colitis-associated colorectal tumorigenesis through remodeling intestinal flora[J]. Phytomedicine, 2022, 102: 154217.
35 Sun Q, Yang H, Liu M, et al. Berberine suppresses colorectal cancer by regulation of Hedgehog signaling pathway activity and gut microbiota[J]. Phytomedicine, 2022, 103: 154227.
36 Chen YX, Gao QY, Zou TH, et al. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study[J]. Lancet Gastroenterol Hepatol, 2020, 5(3): 267-275.
37 Fang S, Guo S, Du S, et al. Efficacy and safety of berberine in preventing recurrence of colorectal adenomas: A systematic review and meta-analysis[J]. J Ethnopharmacol, 2022, 282: 114617.
38 Tokudome S, Kuriki K, Yokoyama Y, et al. Dietary n-3/long-chain n-3 polyunsaturated fatty acids for prevention of sporadic colorectal tumors: a randomized controlled trial in polypectomized participants[J]. Prostaglandins Leukot Essent Fatty Acids, 2015, 94: 1-11.
39 Liu S, Barry EL, Baron JA, et al. Effects of supplemental calcium and vitamin D on the APC/β-catenin pathway in the normal colorectal mucosa of colorectal adenoma patients[J]. Mol Carcinog, 2017, 56(2): 412-424.
40 Emmanouilidou G, Kalopitas G, Bakaloudi DR, et al. Vitamin D as a chemopreventive agent in colorectal neoplasms. A systematic review and meta-analysis of randomized controlled trials[J]. Pharmacol Ther, 2022, 237: 108252.
41 Gao QY, Chen HM, Chen YX, et al. Folic acid prevents the initial occurrence of sporadic colorectal adenoma in Chinese older than 50 years of age: a randomized clinical trial[J]. Cancer Prev Res (Phila), 2013, 6(7): 744-752.
42 Rees JR, Morris CB, Peacock JL, et al. Unmetabolized folic acid, tetrahydrofolate, and colorectal adenoma risk[J]. Cancer Prev Res (Phila), 2017, 10(8): 451-458.

备注/Memo

备注/Memo:
通信作者：杨宇龙，Email: ndkfyyyyl@163.com
更新日期/Last Update: 2024-12-20